Pfizer Gets AAV Capsid Rights From Voyager For Gene Therapy R&D
Executive Summary
Deal Snapshot: Pfizer has 12 months to evaluate a pair of AAV capsids from Voyager’s TRACER platform for use as delivery mechanisms in gene therapy candidates for neurologic and CV indications.
You may also be interested in...
Ex-Novartis Exec Unveils Neurodegeneration Gene Therapy Start-Up AviadoBio
AviadoBio believes it can overcome barriers to making gene therapy work in neurodegenerative diseases, and its new CEO knows what it takes to make a commercial success in the field.
Deal Watch: J&J Partners On Bispecific Antibody R&D With F-Star, Xencor
Janssen Biotech adds to its bispecific antibody pipeline for cancer via pair of collaborations. Ipsen and Accent pair up to investigate new target for acute myeloid leukemia.
Sarepta Leapfrogs Pfizer In The US, Launching DMD Gene Therapy Pivotal Trial
The company has initiated the first pivotal double-blind gene therapy trial in DMD in the US in a tight race with Pfizer.